Literature DB >> 4004556

The role of sincalide cholescintigraphy in the evaluation of patients with acalculus gallbladder disease.

J Pickleman, R L Peiss, R Henkin, B Salo, P Nagel.   

Abstract

Thirty-six patients with biliary colic and normal oral cholecystograms, upper gastrointestinal tract roentgenograms, and results of gallbladder ultrasonography underwent sincalide-stimulated biliary excretion scanning. Nineteen of these patients subsequently underwent cholecystectomies. Gallbladder ejection fractions (EFs) ranged from 0% to 88% (mean, 38%) and nine of 19 patients had exact pain reproduction with sincalide. All patients except one (EF, 35%) were cured of their symptoms. However, five patients were also cured who had a normal EF (greater than 50%). Histologically, 11 gallbladders showed chronic cholecystitis and eight were normal. We conclude that the sincalide biliary excretion scan is a useful test to study this group of patients. In patients with a decreased EF, cholecystectomy can be recommended with a high probability of symptom relief. In patients with normal EFs, clinical judgment is required, as some of these patients (five of five in this series) may still benefit from operation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4004556     DOI: 10.1001/archsurg.1985.01390300043007

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  10 in total

Review 1.  Controversies concerning pathophysiology and management of acalculous biliary-type abdominal pain.

Authors:  Amit Rastogi; Adam Slivka; Arthur James Moser; Arnold Wald
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 2.  Cholecystectomy for biliary dyskinesia: how did we get there?

Authors:  Klaus Bielefeldt; Shreyas Saligram; Susan L Zickmund; Anwar Dudekula; Mojtaba Olyaee; Dhiraj Yadav
Journal:  Dig Dis Sci       Date:  2014-09-06       Impact factor: 3.199

3.  HIDA scan ejection fraction does not predict sphincter of Oddi hypertension or clinical outcome in patients with suspected chronic acalculous cholecystitis.

Authors:  S B Young; M Arregui; K Singh
Journal:  Surg Endosc       Date:  2006-12       Impact factor: 4.584

4.  The cholecystokin provocation HIDA test: recreation of symptoms is superior to ejection fraction in predicting medium-term outcomes.

Authors:  Gareth Morris-Stiff; Gavin Falk; Laurel Kraynak; Steven Rosenblatt
Journal:  J Gastrointest Surg       Date:  2010-09-08       Impact factor: 3.452

5.  Usefulness of gallbladder ejection fraction estimation to predict the recurrence of biliary pain in patients with symptomatic gallstones who did not undergo cholecystectomy.

Authors:  Sung Noh Hong; Jong Kyun Lee; Kyu Taek Lee; Jin Seok Heo; Seong Ho Choi; Poong Lyul Rhee; Seung Woon Paik; Byung Chul Yoo; Jong Chul Rhee
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

6.  Tc-99m-IDA gallbladder kinetics and response to CCK in chronic cholecystitis.

Authors:  F Raymond; L Lepanto; L Rosenthall; G M Fried
Journal:  Eur J Nucl Med       Date:  1988

Review 7.  Biliary dyskinesia: a study of more than 200 patients and review of the literature.

Authors:  A J Canfield; S P Hetz; J P Schriver; H T Servis; T L Hovenga; P T Cirangle; B S Burlingame
Journal:  J Gastrointest Surg       Date:  1998 Sep-Oct       Impact factor: 3.452

8.  Gallbladder ejection fraction and symptom outcome in patients with acalculous biliary-like pain.

Authors:  Nuri Ozden; John K DiBaise
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

9.  Diagnostic stringency and healthcare needs in patients with biliary dyskinesia.

Authors:  Nitin Aggarwal; Klaus Bielefeldt
Journal:  Dig Dis Sci       Date:  2013-08-11       Impact factor: 3.199

10.  Predictor of abnormal gallbladder ejection fraction in patients with atypical biliary pain: Histopathological point of view.

Authors:  Jun Uk Lim; Kwang Ro Joo; Kyu Yeoun Won; Sung-Jig Lim; Sun-Hyung Joo; You-Jung Yang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.